Belantamab Mafodotin Combination for R/R Multiple Myeloma Shows PFS Benefit for Patients With High-Risk Cytogenetic Abnormalities
According to results from the DREAMM-8 clinical trial which evaluated the efficacy and safety of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) for patients with relapsed/refractory (R/R) multiple myeloma (MM) and have high-risk cytogenetic abnormalities (HRCAs), treatment with BPd demonstrated improved survival and response rates compared with treatment with pomalidomide plus bortezomib and dexamethasone (PVd).
These data were presented by Suzanne Trudel, MD, Princess Margaret Cancer Centre, Toronto, Canada, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Patients included had received at least 1 prior line of therapy, including lenalidomide. Overall, 302 patients were randomized to receive BPd (n = 155) and PVd (n = 147). At least one HRCA was found in 44% of patients in the BPd arm and 41% in the PVd arm.
Median progression-free survival (PFS) was higher in the BPd arm (21.1 months; 95% confidence interval [CI], 13.5 to not reached) than the PVd arm (9.2 months; 95% CI, 6.5 to 14.8; hazard ratio [HR], .58; 95% CI, .36 to .95). At 18 months, the PFS remained higher in the BPd group than the PVd group (53% vs 33%).
The overall response rate (ORR) in patients with ≥1 HRCA was higher in the BPd arm (76%; 95% CI, 64.6 to 85.9) than PVd arm (65%; 95% CI, 51.6 to 76.9). PFS benefit with BPd was consistent across cytogenetic subtypes, including patients with del(17p13) (HR, 0.45; 95% CI, .22 to .92) and amp1q (HR, 0.49; 95% CI, .24 to 1.03).
“These data support the potential use of BPd as a standard-of-care regimen in this key [patient] population with a high unmet need,” the researchers concluded.
Source:
Trudel S, Beksac M, Pour L, et al. DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 7533.
